Star Health and Allied Insurance Co (NSE:STARHEALTH) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:STARHEALTH Star Health and Allied Insurance Co Ltd NSE:STARHEALTH
77 GF Score
Price ₹584.75
GF Value ₹588.02
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Star Health and Allied Insurance Co Research & Development?

Star Health and Allied Insurance Co NSE:STARHEALTH +1.33% 77 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:STARHEALTH with a GF Score™ of 77/100 and a GF Value™ of ₹588.02 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Star Health and Allied Insurance Co's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Star Health and Allied Insurance Co  (NSE:STARHEALTH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Star Health and Allied Insurance Co Research & Development Related Terms

Star Health and Allied Insurance Co Research & Development Historical Data

* Premium members only.

The historical data trend for Star Health and Allied Insurance Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Star Health and Allied Insurance Co Research & Development Chart

Star Health and Allied Insurance Co Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Star Health and Allied Insurance Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:STARHEALTH
77GF Score
Star Health and Allied Insurance Co Ltd NSE:STARHEALTH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Star Health and Allied Insurance Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Star Health and Allied Insurance Co (NSE:STARHEALTH) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Star Health and Allied Insurance Co and its competitors.
Is Star Health and Allied Insurance Co's Research & Development too high?
Star Health and Allied Insurance Co's current Research & Development is ₹0 Mil. Overall, Star Health and Allied Insurance Co has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Health and Allied Insurance Co's Research & Development compare to AFL and MET?
Star Health and Allied Insurance Co's Research & Development of ₹0 Mil can be compared against companies in the Insurance industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for an Insurance company?
A good Research & Development depends on the Insurance industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Star Health and Allied Insurance Co and its competitors. Star Health and Allied Insurance Co's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Health and Allied Insurance Co stock overvalued right now?
Based on GuruFocus' analysis, Star Health and Allied Insurance Co (NSE:STARHEALTH) is currently considered Fairly Valued. The stock's GF Value™ is ₹588.02, compared to a current price of ₹584.75 — trading 0.6% below its estimated fair value. The current Research & Development is ₹0 Mil. Star Health and Allied Insurance Co's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Star Health and Allied Insurance Co (NSE:STARHEALTH), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Star Health and Allied Insurance Co (NSE:STARHEALTH) Overvalued in 2026?

Based on GuruFocus' analysis, Star Health and Allied Insurance Co stock appears to be undervalued. The current stock price of ₹584.75 is trading 0.6% below its estimated GF Value™ of ₹588.02. GuruFocus considers Star Health and Allied Insurance Co to be Fairly Valued.

Key valuation signals for NSE:STARHEALTH:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹588.02 vs. price of ₹584.75 (0.6% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the NSE:STARHEALTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Star Health and Allied Insurance Co Business Description

Other Exchanges 543412:India
Address Dr. Radha Krishnan Salai, No. 148, Acropolis, Mylapore, Chennai, TN, IND, 600004
Star Health and Allied Insurance Co Ltd operates a non-life insurance business in India. It focuses on the retail health and group health segments. The company distributes policies through individual agents and also includes corporate agent banks and other corporate agents. It offers various types of insurance plans such as health, accidental, travel, corporate, and others. The operating segments of the company are based on the various types of insurance and include Fire, Marine Cargo, Marine Hull, Aviation, Motor, Workmen Compensation, Engineering, Public Product Liability, Personal Accident, Travel, and Health Insurance. The majority of its revenue is generated from its Health insurance products.
77GF Score

Get the complete analysis for NSE:STARHEALTH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹584.75
Price
₹588.02
GF Value